Benchmarking study 2022

11 agosto 2023 – Swissmedic and the pharmaceutical companies have conducted their 10th benchmarking study of authorisation times for human medicinal products. Comparison with the approval lead times recorded by the European Medicines Agency (EMA), the US Food and Drug Administration (FDA) and Swissmedic enables Swissmedic to directly gauge the performance of the latter as a small, independent national authorisation agency in relation to that of large, international reference authorities.

For more information, see here.